
WilmerHale Reps Tetraphase Pharmaceuticals in \$65M Public Offering of Common Stock

AUGUST 7, 2017

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of \$6.50 per share, with gross proceeds of \$65 million.

[Stuart Falber](#) led the WilmerHale team representing Tetraphase in this transaction, with a team that included [Chris Barnstable-Brown](#), [Emily Gainor](#) and [Tim Kulis](#).

Visit www.tetraphase.com for more information.